Eton Pharmaceuticals, Inc. (ETON): Price and Financial Metrics

Eton Pharmaceuticals, Inc. (ETON): $8.19

-0.29 (-3.42%)

POWR Rating

Component Grades














  • ETON scores best on the Sentiment dimension, with a Sentiment rank ahead of 74.94% of US stocks.
  • ETON's strongest trending metric is Stability; it's been moving up over the last 198 days.
  • ETON ranks lowest in Momentum; there it ranks in the 5th percentile.

ETON Stock Summary

  • Eton Pharmaceuticals Inc's stock had its IPO on November 13, 2018, making it an older stock than merely 5.6% of US equities in our set.
  • ETON's price/sales ratio is 5,125.6; that's higher than the P/S ratio of 99.56% of US stocks.
  • Revenue growth over the past 12 months for Eton Pharmaceuticals Inc comes in at -95.93%, a number that bests just 0.8% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Eton Pharmaceuticals Inc are ATOM, PLXP, CRNX, CRSP, and AQB.
  • ETON's SEC filings can be seen here. And to visit Eton Pharmaceuticals Inc's official web site, go to

ETON Price Target

For more insight on analysts targets of ETON, see our ETON price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.50 Average Broker Recommendation 1.5 (Moderate Buy)

ETON Stock Price Chart Interactive Chart >

Price chart for ETON

ETON Price/Volume Stats

Current price $8.19 52-week high $10.30
Prev. close $8.48 52-week low $4.32
Day low $8.03 Volume 263,600
Day high $8.59 Avg. volume 178,375
50-day MA $7.85 Dividend yield N/A
200-day MA $7.86 Market Cap 200.52M

Eton Pharmaceuticals, Inc. (ETON) Company Bio

Eton Pharmaceuticals Inc. Eton Pharmaceuticals, Inc. is a is a specialty pharmaceutical company, which is focused on developing and commercializing pharmaceutical products. It products include EM-100, ET-103, CT-100, DS-300, DS-200, and DS-100. The Company focuses on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics. EM-100 is an ophthalmic product with a preservative-free formulation of the active ingredient ketotifen, and is indicated for the treatment of allergic conjunctivitis. ET-103 is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule form, and is indicated for the treatment of hypothyroidism. CT-100 is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino acid chain of injectable product H.P. Acthar Gel. DS-300 is a patent-pending injectable product candidate indicated to treat nutritional deficiencies. DS-200 is an injectable product candidate indicated to treat pain management.

ETON Latest News Stream

Event/Time News Detail
Loading, please wait...

ETON Latest Social Stream

Loading social stream, please wait...

View Full ETON Social Stream

Latest ETON News From Around the Web

Below are the latest news stories about Eton Pharmaceuticals Inc that investors may wish to consider to help them evaluate ETON as an investment opportunity.

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q4 2020 Results - Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) Q4 2020 Earnings Conference Call March 16, 2021 16:30 ET Company Participants David Krempa - Vice President, Business Development Sean Brynjelsen - Chief Executive Officer Wilson Troutman - Chief Financial Officer Paul Stickler - Senior Vice President, Sales and Marketing Conference Call Participants Andrew D’silva -...

SA Transcripts on Seeking Alpha | March 17, 2021

Eton Pharmaceuticals Announces Appointment of Jenn Adams to its Board of Directors

DEER PARK, Ill., March 17, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has appointed Jenn Adams to its board of directors effective March 17, 2021. Ms. Adams brings extensive commercial, operational, and leadership experience in the pharmaceutical industry. “We are pleased to have Jenn join our board. Her experience growing pharmaceutical companies and leading sales organizations will be valuable to Eton as we continue to launch products and grow our commercial organization,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. Ms. Adams’ experience includes leading and growing both Fortune 500 public and private equity-backed companie...

Yahoo | March 17, 2021

Eton Pharmaceuticals Earnings Report: Here’s what to expect from Stock market Insights & financial analysis

Eton Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

Stock Market Daily | March 16, 2021

Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -23.08% and -92.21%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 16, 2021

Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results

DEER PARK, Ill., March 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on business progress. “2020 was a transformational year for Eton and the momentum has continued through the start of 2021. In recent months, we have seen two of our products commercially launched, completed an important value-creating transaction with our neurology portfolio, and expanded our ALKINDI SPRINKLE franchise to include Canada,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “With these recent events, we believe we have a clear pathway to achieve of our goal ...

Yahoo | March 16, 2021

Read More 'ETON' Stories Here

ETON Price Returns

1-mo 9.05%
3-mo -17.11%
6-mo 17.84%
1-year 50.83%
3-year N/A
5-year N/A
YTD 0.74%
2020 12.92%
2019 17.65%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6825 seconds.